ArticleScientific reports2026
Probiotic potential of Lactobacillus acidophilus TMPC 41127 isolated from traditional cheese in inhibiting Salmonella Typhi biofilms and virulence genes.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Probiotic, functional, and safety assessment of Levilactobacillus brevis M3R3 isolated from traditional Khiki cheese.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study comprehensively investigated the probiotic and anti-biofilm potential of the Lactobacillus acidophilus TMPC 41127 strain, isolated from traditional Khiki cheese. Initially, its phenotypic characteristics, including resistance to harsh gastrointestinal conditions (low pH and bile salts) and its ability to colonize (surface hydrophobicity 58.9%, auto-aggregation 47.5%, and adhesion to Caco-2 cells 13.9%), were evaluated. The results showed that the cell-free supernatant (CFS) of this strain has strong antimicrobial effects against pathogens, particularly Salmonella enterica subsp. enterica serovar Typhi (Salmonella Typhi). CFS dose-dependently inhibited the formation of Salmonella Typhi biofilms by 79.52% (1/4×MIC) to 13.16% (4×MIC) and degraded mature biofilms, demonstrating anticancer activity against HeLa, HT-29, and MCF-7 cells (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.